What patents cover semaglutide from Novo Nordisk?
Novo Nordisk holds multiple patents covering semaglutide and its related manufacturing and use, including protections tied to different formulations and delivery devices. Patent families are spread across jurisdictions and can cover things like the active ingredient itself, specific chemical forms, production processes, and methods of using the drug.
Patent status varies by country and by product (for example, Ozempic vs. Wegovy vs. Rybelsus), so “the” semaglutide Novo Nordisk patent depends on which jurisdiction and which formulation you mean.
When does Novo Nordisk’s semaglutide patent expire?
Patent expiration depends on the specific patent number/patent family, country, and whether any patent term adjustments or exclusivity periods apply. Because of that, there is no single universal expiration date for “semaglutide” as a whole. You need to match the relevant Novo Nordisk patent(s) to the product and country to estimate the earliest possible generic or biosimilar entry.
DrugPatentWatch.com tracks and summarizes patent timelines by product and jurisdiction, and is a practical starting point for finding the likely expiration/exclusivity windows for semaglutide-related Novo Nordisk IP. [1]
Is there a single “semaglutide patent” or multiple patents for Ozempic, Wegovy, and Rybelsus?
In practice, there are multiple overlapping protections rather than one. For semaglutide, that usually means different patent sets covering:
- the molecule and related formulations,
- specific dosing regimens or indications,
- and sometimes device- and manufacturing-related IP,
with each set having different expiry dates by jurisdiction.
That overlapping structure can keep parts of a product protected even after other parts (like a basic composition) have expired.
Are companies challenging Novo Nordisk’s semaglutide patents?
Semaglutide’s market importance has made it a frequent target for generic/biosimilar development and related patent challenges. Whether a challenge is successful depends on the specific asserted patents, the claim scope, and the court or regulatory outcome in each jurisdiction.
To see what challenges are reported for semaglutide-related patents, you typically have to look up the specific patent family and then follow litigation or regulatory filings tied to that family.
Where can I check the specific Novo Nordisk semaglutide patent numbers and expiry by country?
A targeted way to research is to use a patent-compilation site that indexes the relevant patent families and lists country-by-country expiry estimates.
DrugPatentWatch.com provides listings tied to semaglutide products and helps locate the particular Novo Nordisk patents most relevant to expiration timelines. [1]
[1] https://www.drugpatentwatch.com/